Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation

Effect of GnRH Antagonist Protocol vs Agonist Long Protocol During Controlled Hyperstimulation (COH)for Assisted Reproduction on IVF Outcome, Peak Estradiol Level, and Duration of Stimulation.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01669291

Enrollment

Registered

2012-08-21

Start date

2012-07-31

Completion date

2014-05-31

Last updated

2014-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fertility

Brief summary

The purpose of this study is to determine if utilizing GnRH antagonists versus agonist long protocol during controlled ovarian stimulation (COH) with human-derived gonadotropins for assisted reproduction affects IVF outcome, peak estradiol level, and duration of stimulation.

Detailed description

No detailed description

Interventions

DRUGBravelle and Menopur

Bravelle and Menopur are used for controlled ovarian stimulation (COH)

DRUGAgonist

Agonist (Lupron) is used to suppress endogenous pituitary LH for the premature LH surges.

DRUGAntagonist

Ganirelix acetate or cetrorelix acetate Agonist is used to suppress endogenous pituitary LH for the premature LH surges.

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

21 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Ages 21-40 (inclusive up to 41) * Day 2-4 FSH \< or equal to 10 * Antimullerian Hormone (AMH) greater than or equal to 1.0 * Between 5 and 20 antral follicles on day 2-4 * Body Mass Index (BMI)\>or equal to 18 and \< or equal to 32

Exclusion criteria

* Smokers * Polycystic Ovarian Disease * Endometriosis greater than Stage I * Testicular aspirated sperm

Design outcomes

Primary

Measure	Time frame
To determine if COH in IVF patients using Bravelle & Menopur with antagonists results in improved or equal IVF results compared to patients using agonist.	One year

Secondary

Measure	Time frame
To determined if COH in IVF patients using Bravelle & Menopur with antagonists results in lower peak estradiol levels compared to agonist	One year
To determine if COH patients using Bravelle & Menopur with antagonist antagonists results inn shorter period of stimulation compared with agonist.	One year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026